Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial

Clicks: 16
ID: 329142
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #500 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective The DOTS trial demonstrated similar clinical outcomes among 200 adults with complicated Staphylococcus aureus bacteremia (SAB) randomized to two doses of dalbavancin or standard-therapy antibiotics after initial clearance. We aimed to determine whether the higher cost of dalbavancin is offset through reductions in medical resource use. Methods We used dates for hospitalizations and antibiotics from the trial starting from randomization. Antibiotic costs were based on generic pricing for dalbavancin and most other antibiotics. Medicare payment rates were used to estimate costs for scenarios representing home-based or clinic-based outpatient antibiotic therapy (OPAT). Results On average, patients randomized to dalbavancin spent 2.2 fewer SAB-related days in the hospital (95%CI: -5.3 to 1.3) and received antibiotics on 24.4 fewer days (95%CI: -29.0 to -19.9). Mean inpatient costs for SAB-related admissions were lower by $5805 (95%CI: -14,311 to 3390) in the dalbavancin group. Antibiotic drug costs were $2343 higher (95%CI: 1728 to 3027), but OPAT costs were lower with dalbavancin by $2469 (95% CI: -2913 to -1970) in the home-based scenario and $1112 (95% CI: -1289 to -914) in the clinic-based scenario. Net costs for SAB-related care were $5931 lower (95%CI: -14,660 to 3004) and $4574 lower (95%CI: -13,312 to 4335) with dalbavancin versus standard-therapy with home-based and clinic-based OPAT, respectively. Among patients with injection drug use (IDU), savings with dalbavancin were approximately $22,000. Conclusions On average, savings from reduced inpatient care and less OPAT fully offset the higher cost of dalbavancin in patients with SAB. Savings were greater in patients with IDU.
Reference Key
openalex_W7213503136 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shelby D. Reed, Yanhong Li, Nicholas Turner, Dana K. Pasquale, Richard H. Drew, Paul Cook, Smitha Zaharoff, Vance G. Fowler, Thomas L Holland
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag567
URL
https://doi.org/10.1093/cid/ciag567
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.